The COVID-19 vaccine breakthroughs have finally pushed mRNA technology into a "sweet spot", Haas said, with proof of concept and increased funding opening the door to a slew of other medical advances.
"What is built up now as (mRNA manufacturing) capacity, is here to stay," Haas said.
CureVac is working on a malaria vaccine with the Gates Foundation, and earlier this year received some "very nice" data on a potential rabies shot.
Haas said mRNA also held huge promise for oncology and could lead to tailored cancer treatments.
With Elon Musk's Tesla, CureVac is developing a "mobile manufacturing unit", akin to a mini RNA factory, that can be shipped anywhere and produce thousands of vaccines in mere days, potentially stopping an outbreak in its tracks.
Haas also sees a future where patients can pop to the pharmacy to pick up "personalised medicine", such as a vaccine to fight their specific tumour and manufactured on site.
